Error: Subscribe to Dental Update to view, or purchase this article.
Article: Volume 49 Number 6 Page 477 - June 2022
Prev Article P477 Next 
Read article
Dental Update 501: 477-480
Special Care Dentistry: An Update for General Dental Practitioners on a New Medication for the Management of Patients with Haemophilia A
CPD: 
0:24 (closes in 30 days)
Feedback: 0 comments, 0 ratings
Abstract: Emicizumab is a new medication used in the treatment of people with haemophilia A and there is little in the current literature providing guidance for dental treatment. It is important to risk assess dental procedures appropriately according to their bleeding risk and to liaise closely with the patient’s haematology team. This article provides an overview of emicizumab, its mechanism of action and implications for dental treatment, as well as examples of surgical management plans provided by the haemophilia team.
Clinical relevance: It is important to liaise closely with the patient’s haemophilia team to ensure provision of safe dental treatment.
Author notes: Stephanie Fenesan, Specialty Registrar in Special Care Dentistry, Department of Sedation and Special Care Dentistry, Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital. Bella Madan, Consultant Haematologist, Centre for Haemostasis and Thrombosis, St Thomas’ Hospital, Guy’s and St Thomas’ NHS Foundation Trust. Najla Nizarali, Consultant in Special Care Dentistry, Department of Sedation and Special Care Dentistry, Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital, London. email: stephaniefenesan@nhs.net
Objective: This article aims to provide the reader with an overview of the dental implications of emicizumab use in patients with haemophilia A.
 |
 |